Loading...
AMPK→mitochondrial protection→dopaminergic neuroprotection
Metformin activates AMPK, which reduces mitochondrial dysfunction, oxidative stress, and neuroinflammation — all implicated in dopaminergic neuron loss in Parkinson's disease. Evidence is robust with 12/12 supportive co-mentions across 12 papers up to 2025, including astroprotective mechanisms and multiple reviews advocating clinical evaluation.
“The potential role of metformin in the treatment of Parkinson's disease”
— The potential role of metformin in the treatment of Parkinson's disease (2020)DOI“Taken together, these results suggest that metformin should be evaluated for the treatment of Parkinson's disease and related neurologic disorders characterized by astrocyte activation.”
— Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging. (2020)DOI“Consequently, this review aims to discuss the astroprotective effect of metformin in PD with regard to the underlying mechanisms.”
— The Effect of Metformin on Astrocytes in Parkinson's Disease: Challenges and Opportunities. (2025)DOI“Metformin rescues Parkinson's disease phenotypes caused by hyperactive mitochondria.”
— Metformin rescues Parkinson's disease phenotypes caused by hyperactive mitochondria. (2020)DOI“Metformin as a potential neuroprotective agent that influence Parkinson's disease.”
— Metformin as a potential neuroprotective agent that influence Parkinson's disease. (2025)DOI“Areas covered: The authors review literature on metformin treatment in Parkinson’s disease, Huntington’s disease and other neurological diseases of the CNS along with neuroprotective effects of AMPK activation and suppression of the mammalian target of rapamycin (mTOR) pathway on peripheral neuropat”
— Metformin as a potential therapeutic for neurological disease: mobilizing AMPK to repair the nervous system (2020)DOI